Epidemiologic characteristics and a prognostic nomogram for patients with vulvar cancer: results from the Surveillance, Epidemiology, and End Results (SEER) program in the United States, 1975 to 2016.
Cancer-Specific Survival
Nomogram
Overall Survival
Receiver Operating Characteristic
Vulvar Cancer
Journal
Journal of gynecologic oncology
ISSN: 2005-0399
Titre abrégé: J Gynecol Oncol
Pays: Korea (South)
ID NLM: 101483150
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
07
02
2023
revised:
29
05
2023
accepted:
24
06
2023
medline:
7
11
2023
pubmed:
21
7
2023
entrez:
21
7
2023
Statut:
ppublish
Résumé
To elucidate clinical characteristics and build a prognostic nomogram for patients with vulvar cancer. The study population was drawn from the Surveillance, Epidemiology, and End Results (SEER) database. Patients were randomly assigned to training and validation sets. Cox proportional hazards model and competing risk model were used to identify the prognostic parameters of overall survival (OS) and cancer-specific survival (CSS) to construct a nomogram. The nomogram was assessed by concordance index (C-index), area under the curve (AUC), calibration plot, and decision curve analysis (DCA). A total of 20,716 patients were included in epidemiological analysis, of whom 7,025 patients were selected in survival analysis, including 4,215 and 2,810 in training and validation sets, respectively. The multivariate Cox model showed that the predictors for OS were age, marital status, histopathology, differentiation and tumor node metastasis (TNM) stages, whether to undergo surgery and chemotherapy. However, the predictors for CSS were age, race, differentiation and TNM stages, whether to undergo surgery and radiation. The C-index for OS and CSS in the training set were 0.76 and 0.80. The AUC in the training set for 1-, 3- and 5-year OS and CSS were 0.84, 0.81, 0.80 and 0.88, 0.85, 0.83, respectively, which was similar in the validation set. The calibration curves showed good agreement between prediction and actual observations. DCA revealed that the nomogram had a better discrimination than TNM stages. The nomogram showed accurate prognostic prediction in OS and CSS for vulvar cancer, which could provide guidance to clinical practice.
Identifiants
pubmed: 37477104
pii: 34.e81
doi: 10.3802/jgo.2023.34.e81
pmc: PMC10627757
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e81Subventions
Organisme : NSFC
ID : 82102994
Organisme : Natural Science Foundation of Guangdong Province
ID : 2020A1414040022
Organisme : Natural Science Foundation of Guangdong Province
ID : 2023A1515012517
Organisme : Nanfang Hospital
ID : 2019C028
Organisme : 2021 Science and Technology Plan Project of Haizhu District
ID : 2022-05
Organisme : Basic and Applied Basic Research Joint Project of City
ID : SL2023A03J00732
Informations de copyright
© 2023. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.
Déclaration de conflit d'intérêts
No potential conflict of interest relevant to this article was reported.
Références
Gynecol Oncol. 1998 Mar;68(3):229-32
pubmed: 9570971
Eur J Cancer Care (Engl). 2016 Jul;25(4):638-46
pubmed: 26880231
J Low Genit Tract Dis. 2020 Jul;24(3):272-276
pubmed: 32205765
Ann Transl Med. 2021 Apr;9(7):525
pubmed: 33987223
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Clin Oncol. 2000 Apr;18(8):1606-13
pubmed: 10764420
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221132035
pubmed: 36217877
Ann Intern Med. 2007 Oct 16;147(8):573-7
pubmed: 17938396
Obstet Gynecol Clin North Am. 2019 Mar;46(1):125-135
pubmed: 30683259
Front Oncol. 2020 Jan 24;10:14
pubmed: 32038988
Int J Gynaecol Obstet. 2022 Mar;156(3):529-538
pubmed: 33899929
J Clin Oncol. 2013 Mar 20;31(9):1188-95
pubmed: 23358969
J Am Acad Dermatol. 2019 Dec;81(6):1387-1396
pubmed: 31349045
Eur J Obstet Gynecol Reprod Biol. 2014 May;176:1-4
pubmed: 24636595
Future Oncol. 2018 Oct;14(25):2589-2598
pubmed: 29742925
J Clin Oncol. 2017 Dec 20;35(36):4057-4065
pubmed: 28777690
Cancers (Basel). 2022 Jan 13;14(2):
pubmed: 35053552
Gynecol Oncol. 2013 Apr;129(1):154-8
pubmed: 23274562
BMC Gastroenterol. 2021 Mar 4;21(1):101
pubmed: 33663420
Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1:7-18
pubmed: 34669204
Cancer Treat Rev. 2019 Feb;73:91-103
pubmed: 30685613
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Int J Gynecol Cancer. 2022 Jun 6;32(6):706-715
pubmed: 35428690
Curr Opin Oncol. 2014 Sep;26(5):508-13
pubmed: 25046205
Nutr Metab (Lond). 2023 Jan 4;20(1):2
pubmed: 36600242
Obstet Gynecol. 2006 Mar;107(3):672-7
pubmed: 16507940
J Natl Cancer Inst. 2002 Mar 6;94(5):334-57
pubmed: 11880473
Mil Med Res. 2021 Aug 11;8(1):44
pubmed: 34380547
Gynecol Oncol. 2021 Jan;160(1):252-259
pubmed: 33139040
Ann Transl Med. 2020 Nov;8(21):1382
pubmed: 33313127
Oncotarget. 2018 Jan 3;9(9):8725-8730
pubmed: 29492231
J Hepatol. 2020 Jan;72(1):75-84
pubmed: 31499131
J Clin Oncol. 2008 Mar 10;26(8):1364-70
pubmed: 18323559
Clin Cancer Res. 2004 Nov 1;10(21):7252-9
pubmed: 15534099
Clin Exp Dermatol. 2019 Aug;44(6):651-653
pubmed: 30618159
Am J Obstet Gynecol. 2009 May;200(5):e52-5
pubmed: 19110228